Start your online consultation today and a clinician will be in touch to discuss whether treatment is right for you
Research shows that 2030% of young adults report needle fear
Although weight-loss specific drugs are now licensed, supply is limited, and as a consequence, off-label prescribing of diabetic drugs has continued to grow (particularly of Ozempic (active ingredient: semaglutide) and Mounjaro (active ingredient: tirzepatide))
The mechanism of action of berberine differs fundamentally from that of GLP-1 agonists
[1] [17] For instance, in pivotal trials of semaglutide for diabetes, headache was reported by approximately 6-8% of participants receiving the medication compared to 5-6% in placebo groups, suggesting a modest but measurable association
We Understand GLP-1RAs: We have already been engaged by several clients to advise them on the potential impact of GLP-1RAs on their business